Primary Biliary Cirrhosis
Conditions
Brief summary
prospective, multicenter, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability and efficacy of saroglitazar magnesium 2 mg, 4 mg in Patients with Primary Biliary Cholangitis (PBC). A total 36 subjects will be enrolled in a ratio of 1:1:1 to receive either saroglitazar magnesium 2 mg or saroglitazar magnesium 4 mg or placebo.
Detailed description
Study SARO.16.004.02 is a prospective, multicenter, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability and efficacy of saroglitazar magnesium 2 mg, 4 mg in Patients with Primary Biliary Cholangitis. A total 36 subjects will be enrolled in a ratio of 1:1:1 to receive either saroglitazar magnesium 2 mg or saroglitazar magnesium 4 mg or placebo. The primary objective is to investigate the effect of a 16-week treatment regimen of Saroglitazar magnesium 2 mg and 4 mg on alkaline phosphatase (ALP) levels in patients with Primary Biliary Cholangitis.
Interventions
Saroglitazar magnesium 2 mg once daily in the morning before breakfast without food, for a period of 16 weeks.
Saroglitazar magnesium 4 mg once daily in the morning before breakfast without food, for a period of 16 weeks.
DRUGPlacebo Oral Tablet
Placebo once daily in the morning before breakfast without food, for a period of 16 weeks.
Sponsors
Zydus Therapeutics Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Masking description
Double-blind
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Males or females, between 18 and 75 years of age, inclusive. 2. a) Patients on therapeutic doses of Ursodeoxycholic acid (UDCA) for ≥12 months and stable therapy for ≥3 months prior to enrolment. OR b) Patients who are unable to tolerate UDCA, and did not receive UDCA for at least 3 months from the date of screening. 3. History of confirmed Primary Biliary Cholangitis Diagnosis, based on American Association for the Study of Liver Disease \[AASLD\] and European Association for Study of the Liver \[EASL\] Practice Guidelines; \[Lindor 2009; EASL 2009\], as demonstrated by the presence of at least≥2 of the following 3 diagnostic factors: * History of elevated Alkaline Phosphatase levels for at least 6 months prior to Screening Visit 1 * Positive antimitochondrial antibodies (AMA) titer or if AMA negative or in low titer (\<1:80) PBC specific antibodies (anti-GP210 and/or anti-SP100 and/or antibodies against the major M2 components \[PDC-E2, 2-oxo-glutaric acid dehydrogenase complex\]) * Liver biopsy consistent with PBC. 4. ALP ≥1.67x upper limit of normal (ULN) at Visit 1 and Visit 2 and with \< 30% variance between the levels from Visit 1 to Visit 2. 5. Contraception: Female patients must be postmenopausal, surgically sterile, or if premenopausal, agree to use ≥ 1 effective method of contraception during the trial. Effective methods of contraception are considered to be Hormonal (e.g., contraceptive pill, patch, intramuscular implant or injection); or Double barrier method, i.e., (a) condom (male or female) or (b) diaphragm, with spermicide; or Intrauterine device (IUD); or Vasectomy (partner). 6. Must provide written informed consent and agree to comply with the trial protocol.
Exclusion criteria
1. Consumption of \>3 units of alcohol per day (\>21 units per week) if male and \>2 units of alcohol per day (\>14 units per week) if female for at least 3 consecutive months in the last 5 years (Note: 1 unit = 12 ounces of beer, 4 ounces of wine or 1 ounce of spirits/hard liquor). 2. History or presence of other concomitant liver diseases including: * Hepatitis B or C virus (HCV, HBV) infection * Primary sclerosing cholangitis (PSC) * Alcoholic liver disease * Definite autoimmune liver disease or overlap syndrome * Non-alcoholic steatohepatitis (NASH) 3. Cirrhosis with complications, including history or presence of: spontaneous bacterial peritonitis, hepatocellular carcinoma, bilirubin \> 2x ULN, ascites, encephalopathy, known esophageal varices or history of variceal bleeding and active or history of hepatorenal syndrome. 4. History of any venous thromboembolism, transient ischemic attack (TIA), intracranial hemorrhage, neoplasm, arteriovenous malformation, vasculitis, bleeding disorder, coagulation disorders or screening blood tests that indicate altered coagulability (e.g. platelet count, activated partial thromboplastin time \[aPTT\], partial thromboplastin time \[PTT\] or thrombin time \[TT\] tests). 5. Patients with INR \> upper limit of normal (ULN) at visit 1. 6. Patients with total bilirubin \> ULN at visit 1 that is not due to Gilbert's syndrome 7. Patients with \>30% increase in ALT, total bilirubin, or Internation normalized ratio (INR) between Visit 1 to Visit 2. 8. Patients with serum creatinine \>ULN according to the gender at Visit 1. 9. Patients with abnormal total creatine kinase (CK) OR lipase OR amylase at Visit 1. 10. Unstable cardiovascular disease, including: * unstable angina, (i.e., new or worsening symptoms of coronary heart disease within the past 3 months), acute coronary syndrome within the past 6 months, acute myocardial infarction in the past 3 months or heart failure of New York Heart Association class (III - IV) or worsening congestive heart failure, or coronary artery intervention, within the past 6 months * history of (within prior 3 months) or current unstable cardiac dysrhythmias * uncontrolled hypertension (systolic blood pressure \[BP\] \>160 mmHg and/or diastolic BP \>100 mmHg) * stroke or transient ischemic attack within the prior 6 months 11. History of malignancy in the past 5 years and/or active neoplasm with the exception of resolved superficial nonmelanoma skin cancer. 12. Contraindications to Saroglitazar magnesium or has any conditions affecting the ability to evaluate the effects of Saroglitazar magnesium. 13. Known allergy, sensitivity or intolerance to the study drug, comparator or formulation ingredients. 14. Participation in any other clinical study within the previous 3 months of screening. 15. Illicit substance abuse within the past 6 months. 16. History or other evidence of severe illness or any other conditions that would make the patient, in the opinion of the investigator, unsuitable for the study (such as poorly controlled psychiatric disease, human immunodeficiency virus (HIV), coronary artery disease or active gastrointestinal conditions that might interfere with drug absorption).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Effect of a 16-week Treatment Regimen of Saroglitazar Magnesium 2 mg and 4 mg on Alkaline Phosphatase (ALP) Levels in Patients With Primary Biliary Cholangitis. | Baseline and Week 16 | Change in ALP levels after 16 weeks of Saroglitazar magnesium 2 mg and 4 mg treatment. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Saroglitazar Magnesium 2 mg Saroglitazar magnesium 2 mg tablet Once daily for 16 weeks
Saroglitazar magnesium 2 mg: Saroglitazar magnesium 2 mg once daily in the morning before breakfast without food, for a period of 16 weeks. | 14 |
| Saroglitazar Magnesium 4 mg Saroglitazar magnesium 4 mg tablet Once daily for 16 weeks
Saroglitazar magnesium 4 mg: Saroglitazar magnesium 4 mg once daily in the morning before breakfast without food, for a period of 16 weeks. | 13 |
| Placebo Placebo tablet Once daily for 16 weeks
Placebo Oral Tablet: Placebo once daily in the morning before breakfast without food, for a period of 16 weeks. | 10 |
| Total | 37 |
Baseline characteristics
| Characteristic | Saroglitazar Magnesium 2 mg | Saroglitazar Magnesium 4 mg | Placebo | Total |
|---|---|---|---|---|
| Age, Continuous | 57.21 Years STANDARD_DEVIATION 9.67 | 55.08 Years STANDARD_DEVIATION 8 | 59.20 Years STANDARD_DEVIATION 7.3 | 57.00 Years STANDARD_DEVIATION 8.44 |
| Body Mass Index | 27.71 kg/m^2 STANDARD_DEVIATION 6.39 | 29.62 kg/m^2 STANDARD_DEVIATION 6.49 | 32.30 kg/m^2 STANDARD_DEVIATION 7.37 | 29.62 kg/m^2 STANDARD_DEVIATION 6.77 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 3 Participants | 1 Participants | 0 Participants | 4 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 10 Participants | 12 Participants | 10 Participants | 32 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 1 Participants | 1 Participants | 3 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 13 Participants | 11 Participants | 9 Participants | 33 Participants |
| Sex: Female, Male Female | 13 Participants | 13 Participants | 10 Participants | 36 Participants |
| Sex: Female, Male Male | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 14 | 0 / 13 | 0 / 10 |
| other Total, other adverse events | 12 / 14 | 11 / 13 | 8 / 10 |
| serious Total, serious adverse events | 2 / 14 | 0 / 13 | 0 / 10 |
Outcome results
Primary
Effect of a 16-week Treatment Regimen of Saroglitazar Magnesium 2 mg and 4 mg on Alkaline Phosphatase (ALP) Levels in Patients With Primary Biliary Cholangitis.
Change in ALP levels after 16 weeks of Saroglitazar magnesium 2 mg and 4 mg treatment.
Time frame: Baseline and Week 16
Population: Modified intent-to-treat population
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Saroglitazar Magnesium 2 mg | Effect of a 16-week Treatment Regimen of Saroglitazar Magnesium 2 mg and 4 mg on Alkaline Phosphatase (ALP) Levels in Patients With Primary Biliary Cholangitis. | -163.82 U/L | Standard Deviation 111.84 |
| Saroglitazar Magnesium 4 mg | Effect of a 16-week Treatment Regimen of Saroglitazar Magnesium 2 mg and 4 mg on Alkaline Phosphatase (ALP) Levels in Patients With Primary Biliary Cholangitis. | -162.31 U/L | Standard Deviation 113.98 |
| Placebo | Effect of a 16-week Treatment Regimen of Saroglitazar Magnesium 2 mg and 4 mg on Alkaline Phosphatase (ALP) Levels in Patients With Primary Biliary Cholangitis. | -11.15 U/L | Standard Deviation 27.36 |
p-value: 0.0001paired t-test
p-value: 0.0002paired t-test